ReviewHNO2026
[Update on salivary gland surgery].
Review in HNO, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveRecent years have seen publication of studies on salivary gland surgery with a major impact on daily practice. This applies to both the surgical treatment of benign and malignant tumors and to the treatment of obstructive and inflammatory diseases of the salivary glands. In the case of tumors, extracapsular dissection has led to a shift toward de-escalation of facial exposure and resection with low morbidity over the past 20 years. For inflammatory and obstructive diseases, minimally invasive treatment methods have become established over the past 35 years, especially over the past 10. This paper provides an update on salivary gland surgery. Part 1 deals with tumor surgery and part 2 with the surgical therapy of obstructive and inflammatory diseases. MATERIALS AND
methodsThis article represents a compilation of current developments based on the latest literature, with a focus on the past decade and the authors' our own experience.
resultsExtracapsular dissection is superior to superficial parotidectomy in terms of Frey syndrome, operating time, esthetic appearance, and transient and permanent facial function-provided the indications are appropriate. In malignant tumors without infiltration of the facial nerve, the latter should be preserved in the context of complete parotidectomy. Radical parotidectomy is only indicated in cases of facial nerve infiltration. Elective ipsilateral neck dissection is indicated for T3/4 tumors, high-grade carcinomas, and adenoid cystic carcinomas. Therapeutic and interventional sialendoscopy and sialendoscopy-assisted surgical procedures dominate the treatment of obstructive and inflammatory salivary gland diseases and can also be important in cases of salivary duct injury.
conclusionThe indication for surgery and the choice of surgical technique depend on the location and biological behavior of the tumor. Based on the developments outlined above, resection of the major salivary glands is indicated in less than 5% of cases of obstructive or inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.